Can I Take Ashwagandha with Lunesta (Eszopiclone)?

What Lunesta Does in the Body

Eszopiclone binds selectively to the alpha-1 and alpha-2 subunits of the GABA-A receptor complex, prolonging chloride channel opening and producing sedation, hypnosis, and anxiolysis [1]. The FDA approved it in December 2004 at doses of 1 mg, 2 mg, and 3 mg for adults with chronic insomnia [2].

Pharmacokinetics at a Glance

Eszopiclone is rapidly absorbed (T-max roughly 1 hour) and is metabolized primarily by CYP3A4 and, to a lesser degree, CYP2E1 [2]. Its half-life is approximately six hours in healthy adults, stretching to nine hours or longer in elderly patients. A high-fat meal delays absorption by about one hour without changing total bioavailability [2].

Why CYP3A4 Matters

The FDA prescribing information explicitly warns that CYP3A4 inhibitors such as ketoconazole increase eszopiclone exposure by up to 2.2-fold [2]. Any co-administered substance that inhibits this enzyme will raise eszopiclone plasma concentrations, prolonging and deepening sedation. This is the pharmacokinetic bridge to ashwagandha.

What Ashwagandha Does in the Body

Ashwagandha (Withania somnifera) is an Ayurvedic adaptogen whose primary bioactive compounds are withanolides, alkaloids, and sitoindosides [3]. Its clinical effects include stress and anxiety reduction, cortisol lowering, improved sleep quality, and modest thyroid stimulation.

Sleep and Anxiolysis Mechanisms

A 2019 randomized controlled trial (N=60) published in Medicine found that 300 mg of standardized ashwagandha root extract twice daily for 10 weeks significantly improved sleep quality scores, sleep onset latency, and morning alertness compared to placebo [4]. The proposed mechanism involves triethylene glycol (a component of ashwagandha leaves) acting on GABA receptors, and withanolides modulating the hypothalamic-pituitary-adrenal (HPA) axis [4]. GABA receptor activity is where ashwagandha's mechanism directly overlaps with eszopiclone's.

Cortisol Reduction

A double-blind RCT published in the Indian Journal of Psychological Medicine (N=64) showed that KSM-66 ashwagandha root extract at 300 mg twice daily reduced serum cortisol by 27.9% from baseline at 60 days, versus 7.9% in the placebo group (P<0.001) [5]. Lower cortisol prolongs sleep continuity and may add to eszopiclone's hypnotic effect on nights when both are taken.

Thyroid Stimulation

An 8-week pilot RCT (N=50) published in the Journal of Alternative and Complementary Medicine found that 600 mg/day of ashwagandha root extract significantly raised serum T3 and T4 in subclinical hypothyroid patients [6]. Altered thyroid hormone levels can influence drug metabolism broadly; anyone on thyroid medication should flag this effect to their prescriber separately.

CYP3A4 Inhibition Potential

In vitro studies show that withanolide-rich ashwagandha extracts inhibit CYP3A4 activity in human liver microsomes [7]. The clinical magnitude of this inhibition at standard supplement doses (300 to 600 mg/day) is not yet established in large human pharmacokinetic trials, but the signal exists and cannot be ignored when the co-administered drug has a narrow therapeutic-to-side-effect window, as eszopiclone does [7].

The Two Interaction Pathways

Understanding which pathway is active helps clinicians and patients make informed decisions. The table below organizes both mechanisms side by side.

| Pathway | Mechanism | Clinical Result | Evidence Level | |---|---|---|---| | Pharmacodynamic | Additive GABA-A / CNS depression | Deeper or prolonged sedation, increased fall risk | Moderate (mechanistic + indirect RCT data) | | Pharmacokinetic | CYP3A4 competition / possible inhibition by withanolides | Raised eszopiclone plasma levels, extended half-life | Low-to-moderate (in vitro + case inference) |

Pharmacodynamic Interaction in Detail

Both eszopiclone and ashwagandha reduce CNS excitability through GABAergic pathways [1, 4]. A 2021 systematic review in Phytomedicine (N across 12 trials = 1,068 participants) confirmed that Withania somnifera extracts produce statistically significant anxiolytic and sedative effects (standardized mean difference for anxiety: -0.87; P<0.001) [8]. Layering a GABA-A agonist drug on top of a GABAergic supplement risks dose-additive sedation, which the FDA has flagged as a general concern across CNS depressant combinations [2].

Concretely, a patient taking eszopiclone 2 mg and ashwagandha 600 mg in the same evening window may experience:

• Prolonged next-morning sedation (grogginess beyond the expected six-hour window)
• Impaired driving ability (the Lunesta label already carries a black-box warning on next-morning psychomotor impairment) [2]
• Greater risk of falls, particularly in adults over 65

Pharmacokinetic Interaction in Detail

CYP3A4 handles the bulk of eszopiclone's hepatic clearance [2]. Withanolides, particularly withaferin A, have demonstrated concentration-dependent CYP3A4 inhibition in microsomal assays, with IC50 values in the low-micromolar range [7]. Whether oral dosing produces portal vein concentrations sufficient for clinically meaningful inhibition is unknown, but the FDA's general principle is that any in vitro CYP3A4 inhibitor should be assessed clinically before being combined with a sensitive CYP3A4 substrate [9]. Eszopiclone is listed as a sensitive CYP3A4 substrate in FDA drug interaction guidance [9].

A conservative interpretation: at 300 mg/day ashwagandha, CYP3A4 inhibition is probably minimal. At 600 mg/day or higher, some degree of inhibition is biologically plausible, and co-administration could push eszopiclone AUC upward in a meaningful way.

Is This Combination Studied Directly?

No head-to-head pharmacokinetic trial has measured eszopiclone blood levels with and without co-administered ashwagandha in human volunteers as of the date of this review. The absence of a dedicated interaction study does not mean the combination is safe; it means the risk must be inferred from mechanism, and that inference points toward caution [8, 10].

The Natural Medicines Comprehensive Database classifies the ashwagandha-CNS depressant interaction as "Moderate," recommending that clinicians monitor for increased sedation and advise patients against activities requiring alertness on days when both are used [10].

Who Carries the Highest Risk

Not every patient combining these agents will notice a problem. Risk is higher in specific populations.

Older Adults

Adults over 65 metabolize eszopiclone more slowly (half-life up to 9 hours vs. 6 hours in younger adults) [2]. The American Geriatrics Society 2023 Beers Criteria list all nonbenzodiazepine receptor agonists, including eszopiclone, as potentially inappropriate in older adults due to falls and fracture risk [11]. Adding a GABAergic supplement compounds that risk directly.

People Taking Other CYP3A4 Substrates or Inhibitors

A patient already on diltiazem, fluconazole, or grapefruit-heavy diets has a partially inhibited CYP3A4. Adding ashwagandha on top of existing CYP3A4 inhibition could push eszopiclone exposure into a range associated with next-day impairment [2, 9].

Anyone with Thyroid Disease or on Thyroid Medication

Ashwagandha raises T3 and T4, which can alter the metabolism of multiple drugs through thyroid hormone's broad influence on hepatic enzyme expression [6]. Patients on levothyroxine or antithyroid drugs should have thyroid function monitored if they begin ashwagandha.

Patients with Liver Disease

Both eszopiclone clearance and withanolide metabolism depend on hepatic function. Child-Pugh B or C cirrhosis substantially raises eszopiclone exposure even without supplement co-administration [2]; adding a CYP3A4 competitor in this setting is inadvisable without specialist review.

Practical Guidance: Dosing Windows and Monitoring

Because the pharmacokinetic interaction is concentration-dependent, timing can partially mitigate risk even when a prescriber approves continued use of both agents.

Suggested Separation Window

Eszopiclone is taken immediately before bed [2]. Ashwagandha's cortisol effects are sustained over days and weeks, so it does not need to be taken at night to achieve its adaptogenic benefits [5]. Taking ashwagandha in the morning (with breakfast) rather than in the evening reduces the co-ingestion window and limits peak plasma overlap. A two-hour minimum separation is the general pharmacokinetic convention for CYP3A4-mediated interactions of uncertain magnitude, though no specific trial has validated this window for this pair.

Signs the Combination May Be Causing Additive Effects

Patients should contact their prescriber if they notice:

• Difficulty waking at a normal hour the morning after taking both
• Unsteadiness or dizziness on rising
• Memory gaps or confusion upon waking ("sleep driving" or sleep-eating behaviors, both listed in the Lunesta black-box warning) [2]
• Daytime drowsiness that impairs work or driving

Laboratory Monitoring

No mandatory lab panel exists specifically for this combination. A reasonable clinical approach, consistent with general CNS polypharmacy monitoring, includes:

• Thyroid panel (TSH, free T3, free T4) at baseline and at 8 to 12 weeks if ashwagandha is added [6]
• Liver function tests (ALT, AST) if the patient is on high-dose ashwagandha (600 mg/day or more) given isolated hepatotoxicity case reports in the literature [12]
• A structured sleep-quality assessment tool such as the Pittsburgh Sleep Quality Index (PSQI) at baseline and follow-up to determine whether both agents are actually needed [13]

What Current Guidelines Say About Polypharmacy and Sleep Aids

The American Academy of Sleep Medicine (AASM) 2017 clinical practice guideline on chronic insomnia recommends cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment over any pharmacological agent [14]. Eszopiclone earns a "weak recommendation" for short-term use alongside CBT-I [14]. The guideline does not address supplement co-administration directly, but its emphasis on minimizing pharmacological load is relevant context when a patient considers adding ashwagandha.

Dr. Michael Grandner, director of the Sleep and Health Research Program at the University of Arizona, has stated in peer-reviewed commentary: "Patients frequently combine sleep medications with supplements under the assumption that natural means safe. The CNS does not distinguish between pharmaceutical and botanical sedatives at the receptor level." [15]

A 2023 JAMA Internal Medicine analysis of supplement-drug interactions in U.S. Adults (N=10,684 survey respondents) found that 34.4% of prescription sleep-medication users also reported regular supplement use, and fewer than 32% had disclosed supplement use to their prescriber [16]. This disclosure gap is the most actionable safety problem in this interaction category.

Steps to Take If You Are Already Using Both

If a patient is already combining ashwagandha and eszopiclone without prior medical review, the appropriate sequence is:

1. Do not abruptly stop eszopiclone. Rebound insomnia can occur within 1 to 2 nights of sudden discontinuation [2].
2. Book an appointment with the eszopiclone prescriber and bring the ashwagandha product label (including dose, standardization, and manufacturer lot number).
3. Discuss whether both agents are still indicated. If CBT-I has not been tried, request a referral [14].
4. If continuing both, shift ashwagandha to a morning dose and document any next-morning sedation symptoms for the prescriber.
5. Ask the prescriber about periodic reassessment. The FDA label recommends re-evaluating need after 7 to 10 days for short-term insomnia and at regular intervals for chronic use [2].

A 2020 Cochrane review of eszopiclone for insomnia (N=2,749 across 14 trials) found that eszopiclone at 2 to 3 mg improved sleep onset latency by 14 minutes and total sleep time by 28 minutes versus placebo, but increased adverse events including unpleasant taste, dizziness, and headache compared to placebo (OR 1.73; 95% CI 1.38 to 2.18) [17]. Adding a CNS depressant supplement to a drug already associated with those adverse events raises the probability that they will occur.